A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection

Table 1 Clinical data and seroreactive response to VLPs or HPV-16 E6 and E7 antigenic peptides in sera from CIN 1 patients.

gVLP (1.10)	VLP-L1 (1.08)	cVLP (1.00)	E7(37-54) (0.33)	E7(49-57) (0.38)	E6(16-30) (0.36)	Sera Neutralizing dilution to VLPs	Number of sexual partners [3.0]	Number of Pregnancies [3.5]
		1.933	0.364	0.475	0.364	-	5	4
		1.790	0.433	0.473	0.392	-	2	3
		1.760	0.337	0.493	0.434	-	2	5
		1.670	0.264	0.466	0.214	-	1	2
1.628	1.751	1.633	0.293	0.342	0.301	1:100	2	5
		1.791	0.311	0.241	0.253	1:100	2	4
1.299	1.423	1.969	0.386	0.425	0.444	-	3	3
		1.686	0.371	0.446	0.500	-	5	4
		1.790	0.299	0.277	0.297	1:100	4	2
		1.113	0.324	0.386	0.269	1:200	2	3
		1.383	0.537	0.571	0.409	-	3	4

Shown are the IgG serum antibody absorbances to VLPs or HPV-16 E6 and E7 antigenic peptides from CIN 1 subjects from Group H (Figure 1). The cut-off values for a high seropositive response to each antigen are shown in parenthesis. Serum dilutions with neutralizing activity to VLPs are also indicated. Absence of neutralizing activity is indicated by "(-)". Mean numbers of sexual partners and pregnancies are shown in square brackets.

ISSN: 1743-422X